Welcome to our dedicated page for Ceryvyn Therapeutics SEC filings (Ticker: OPTEY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ceryvyn Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ceryvyn Therapeutics's regulatory disclosures and financial reporting.
Opthea Ltd ownership update: Regal Partners Funds Management Pty Limited and Regal Partners Limited report beneficial ownership of 45,215,626 Ordinary Shares, representing 3.31% of the class. The filing states shared voting and dispositive power over the 45,215,626 shares. Each American Depositary Share represents 8 Ordinary Shares.